RU2739037C3 - Композиция для контролируемой стимуляции яичников - Google Patents
Композиция для контролируемой стимуляции яичниковInfo
- Publication number
- RU2739037C3 RU2739037C3 RU2017106756A RU2017106756A RU2739037C3 RU 2739037 C3 RU2739037 C3 RU 2739037C3 RU 2017106756 A RU2017106756 A RU 2017106756A RU 2017106756 A RU2017106756 A RU 2017106756A RU 2739037 C3 RU2739037 C3 RU 2739037C3
- Authority
- RU
- Russia
- Prior art keywords
- sialylation
- fsh
- pharmaceutical composition
- patient
- total
- Prior art date
Links
- 230000002611 ovarian Effects 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 13
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 13
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000009450 sialylation Effects 0.000 claims 6
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 claims 4
- 208000000509 infertility Diseases 0.000 claims 4
- 230000036512 infertility Effects 0.000 claims 4
- 231100000535 infertility Toxicity 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (4)
1. Применение фармацевтической композиции, содержащей фолликулостимулирующий гормон (ФСГ), для лечения бесплодия у пациентки, имеющей сывороточный уровень антимюллеровского гормона (АМГ) не менее 35 пмоль/л, где фармацевтическая композиция предназначена для введения в дозе, равной от 0,10 до 0,11 мкг рекомбинантного ФСГ на кг массы тела пациента в сутки, и где указанный ФСГ включает а2,3- и а2,6-сиалирование, где от 11,5% до 15,76% общего сиалирования представляет собой а2,6-сиалирование и от 84,24 до 88,5% общего сиалирования представляет собой а2,3-сиалирование.
2. Применение фармацевтической композиции, содержащей ФСГ, для лечения бесплодия у пациентки, имеющей риск синдрома гиперстимуляции яичников (СГСЯ), имеющей сывороточный уровень АМГ не менее 35 пмоль/л, где фармацевтическая композиция предназначена для введения в дозе, равной от 0,10 до 0,11 мкг рекомбинантного ФСГ на кг массы тела пациента в сутки, и где указанный ФСГ включает а2,3- и а2,6-сиалирование, где от 11,5% до 15,76% общего сиалирования представляет собой а2,6-сиалирование и от 84,24 до 88,5% общего сиалирования представляет собой а2,3-сиалирование.
3. Применение фармацевтической композиции, содержащей ФСГ, для лечения бесплодия у пациентки, имеющей риск синдрома гиперстимуляции яичников (СГСЯ) и имеющей сывороточный уровень АМГ не менее 15 пмоль/л, где фармацевтическая композиция предназначена для введения в дозе, равной от 0,10 до 0,19 мкг рекомбинантного ФСГ на кг массы тела пациента в сутки, и где указанный ФСГ включает а2,3- и а2,6-сиалирование, где от 11,5% до 15,76% общего сиалирования представляет собой а2,6-сиалирование и от 84,24 до 88,5% общего сиалирования представляет собой а2,3-сиалирование.
4. Применение фармацевтической композиции, содержащей рекомбинантный фолликулостимулирующий гормон (ФСГ), для лечения бесплодия у пациентки, имеющей сывороточный уровень АМГ 0,05 пмоль/л или выше, где фармацевтическая композиция содержит дозу, равную 12 мкг рекомбинантного ФСГ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11176803.2 | 2011-08-08 | ||
| EP11176803 | 2011-08-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102924A Division RU2613324C3 (ru) | 2011-08-08 | 2012-08-08 | Композиция для контролируемой стимуляции яичников |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020137769A Division RU2020137769A (ru) | 2020-11-18 | Композиция для контролируемой стимуляции яичников |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| RU2017106756A RU2017106756A (ru) | 2019-01-23 |
| RU2017106756A3 RU2017106756A3 (ru) | 2020-07-09 |
| RU2739037C2 RU2739037C2 (ru) | 2020-12-21 |
| RU2739037C3 true RU2739037C3 (ru) | 2021-09-08 |
Family
ID=46785372
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102924A RU2613324C3 (ru) | 2011-08-08 | 2012-08-08 | Композиция для контролируемой стимуляции яичников |
| RU2017106756A RU2739037C3 (ru) | 2011-08-08 | 2012-08-08 | Композиция для контролируемой стимуляции яичников |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102924A RU2613324C3 (ru) | 2011-08-08 | 2012-08-08 | Композиция для контролируемой стимуляции яичников |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9694052B2 (ru) |
| EP (9) | EP3756681B1 (ru) |
| JP (5) | JP6161609B2 (ru) |
| KR (8) | KR20250126867A (ru) |
| CN (2) | CN107281470A (ru) |
| AR (1) | AR087476A1 (ru) |
| AU (3) | AU2012293647B2 (ru) |
| BR (2) | BR122020001644B1 (ru) |
| CA (1) | CA2844282A1 (ru) |
| CY (1) | CY1117214T1 (ru) |
| DK (8) | DK3646881T3 (ru) |
| ES (8) | ES2977682T3 (ru) |
| FI (2) | FI3756681T3 (ru) |
| HR (8) | HRP20240420T1 (ru) |
| HU (8) | HUE054312T2 (ru) |
| IL (2) | IL300380A (ru) |
| JO (1) | JO3092B1 (ru) |
| LT (7) | LT3756681T (ru) |
| MX (5) | MX348981B (ru) |
| PL (8) | PL2741763T3 (ru) |
| PT (6) | PT3195875T (ru) |
| RS (8) | RS61843B1 (ru) |
| RU (2) | RU2613324C3 (ru) |
| SA (1) | SA112330762B1 (ru) |
| SI (8) | SI3756681T1 (ru) |
| SM (1) | SMT201600038B (ru) |
| TR (2) | TR201911269T4 (ru) |
| TW (2) | TWI555530B (ru) |
| WO (1) | WO2013020996A1 (ru) |
| ZA (2) | ZA201400952B (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| EP3237608B1 (en) * | 2014-12-22 | 2019-10-09 | F. Hoffmann-La Roche AG | Cmp-dependent sialidase activity |
| EP3283097B1 (en) | 2015-04-17 | 2020-02-12 | Ferring B.V. | Fsh for treatment of infertility |
| MX381279B (es) | 2015-06-26 | 2025-03-12 | Ferring Bv | Métodos de purificación y/o inactivación viral. |
| KR20180052128A (ko) * | 2015-09-17 | 2018-05-17 | 글리코토페 게엠베하 | 증가된 안정성을 갖는 포유동물 난포-자극 호르몬 조성물 |
| IL311335A (en) * | 2016-09-30 | 2024-05-01 | Sumitomo Pharma Switzerland Gmbh | Methods for treating female infertility |
| JP6856819B2 (ja) | 2017-09-01 | 2021-04-14 | フェリング ベスローテン フェンノートシャップ | 調節卵巣刺激のための組成物 |
| SI3787667T1 (sl) * | 2018-04-30 | 2025-06-30 | Ferring B.V. | Sestavek za nadzorovano stimulacijo jajčnikov |
| TWI846743B (zh) | 2018-10-17 | 2024-07-01 | 荷蘭商菲林公司 | 用於控制性卵巢刺激之組成物及方法 |
| US11576920B2 (en) | 2019-03-18 | 2023-02-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
| CN110841060A (zh) * | 2019-11-21 | 2020-02-28 | 上海交通大学 | Choriogonadotropin alfa在治疗多囊卵巢综合征中的应用 |
| TW202237173A (zh) | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
| AU2022451605A1 (en) | 2022-04-01 | 2024-09-26 | Ferring B.V. | Mixed protocol for treatment of infertility |
| AU2023275943A1 (en) | 2022-05-26 | 2024-10-17 | Ferring B.V. | Compositions and methods for treatment of infertility in males |
| JP2025521461A (ja) | 2022-07-08 | 2025-07-10 | フェリング ベスローテン フェンノートシャップ | 子宮内授精（ｉｕｉ）のための組成物及び方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW518235B (en) | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| EP1074265A1 (en) * | 1999-08-03 | 2001-02-07 | Erasmus Universiteit Rotterdam | Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility |
| EA007030B1 (ru) | 2001-10-22 | 2006-06-30 | Апплайд Резеч Системз Арс Холдинг Н.В. | Гонадотропины для фолликулогенеза |
| US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| US8501719B2 (en) * | 2005-11-08 | 2013-08-06 | American Infertility Of New York | Androgen treatment in females |
| TWI488640B (zh) * | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| DE102010007984B4 (de) | 2010-02-15 | 2012-01-26 | Hochland Ag | Form- und Kühlvorrichtung für eine fließfähige, aufgeschmolzene Lebensmittelmasse |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| WO2012016576A1 (en) | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| SI2621517T2 (sl) | 2010-09-29 | 2023-11-30 | Ferring B.V. | Sestavek za uporabo pri zdravljenju neplodnosti |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
-
2012
- 2012-07-18 JO JOP/2012/0197A patent/JO3092B1/ar active
- 2012-07-23 TW TW101126453A patent/TWI555530B/zh active
- 2012-07-23 TW TW105124123A patent/TWI657822B/zh active
- 2012-08-07 AR ARP120102883A patent/AR087476A1/es not_active Application Discontinuation
- 2012-08-07 SA SA112330762A patent/SA112330762B1/ar unknown
- 2012-08-08 FI FIEP20186935.1T patent/FI3756681T3/fi active
- 2012-08-08 HU HUE19213649A patent/HUE054312T2/hu unknown
- 2012-08-08 LT LTEP20186935.1T patent/LT3756681T/lt unknown
- 2012-08-08 KR KR1020257026973A patent/KR20250126867A/ko active Pending
- 2012-08-08 RS RS20210603A patent/RS61843B1/sr unknown
- 2012-08-08 RS RS20181263A patent/RS57897B1/sr unknown
- 2012-08-08 EP EP20186935.1A patent/EP3756681B1/en active Active
- 2012-08-08 LT LTEP18167552.1T patent/LT3395357T/lt unknown
- 2012-08-08 CA CA2844282A patent/CA2844282A1/en active Pending
- 2012-08-08 FI FIEP21207717.6T patent/FI4005588T3/fi active
- 2012-08-08 PL PL12753675T patent/PL2741763T3/pl unknown
- 2012-08-08 DK DK19213649.7T patent/DK3646881T3/da active
- 2012-08-08 ES ES21207717T patent/ES2977682T3/es active Active
- 2012-08-08 KR KR1020207029774A patent/KR20200121918A/ko not_active Ceased
- 2012-08-08 ES ES17154031.3T patent/ES2692774T3/es active Active
- 2012-08-08 EP EP23208228.9A patent/EP4306174A3/en active Pending
- 2012-08-08 PL PL14184409T patent/PL2821080T3/pl unknown
- 2012-08-08 HU HUE14184409A patent/HUE041769T2/hu unknown
- 2012-08-08 KR KR1020217037512A patent/KR102499969B1/ko active Active
- 2012-08-08 SI SI201232033T patent/SI3756681T1/sl unknown
- 2012-08-08 IL IL300380A patent/IL300380A/en unknown
- 2012-08-08 PT PT17154031T patent/PT3195875T/pt unknown
- 2012-08-08 SI SI201231493T patent/SI2821080T1/sl unknown
- 2012-08-08 PL PL19213649T patent/PL3646881T3/pl unknown
- 2012-08-08 HU HUE21207717A patent/HUE066158T2/hu unknown
- 2012-08-08 ES ES14184409T patent/ES2704878T3/es active Active
- 2012-08-08 LT LTEP21207717.6T patent/LT4005588T/lt unknown
- 2012-08-08 MX MX2014001489A patent/MX348981B/es active IP Right Grant
- 2012-08-08 PL PL18167552T patent/PL3395357T3/pl unknown
- 2012-08-08 HR HRP20240420TT patent/HRP20240420T1/hr unknown
- 2012-08-08 BR BR122020001644-2A patent/BR122020001644B1/pt active IP Right Grant
- 2012-08-08 US US14/237,697 patent/US9694052B2/en active Active
- 2012-08-08 KR KR1020147005938A patent/KR102014469B1/ko active Active
- 2012-08-08 HU HUE19164277A patent/HUE053716T2/hu unknown
- 2012-08-08 TR TR2019/11269T patent/TR201911269T4/tr unknown
- 2012-08-08 LT LTEP19164277.6T patent/LT3566712T/lt unknown
- 2012-08-08 MX MX2017004482A patent/MX381278B/es unknown
- 2012-08-08 HU HUE18167552 patent/HUE044610T2/hu unknown
- 2012-08-08 SI SI201231884T patent/SI3566712T1/sl unknown
- 2012-08-08 PL PL20186935.1T patent/PL3756681T3/pl unknown
- 2012-08-08 EP EP12753675.3A patent/EP2741763B1/en active Active
- 2012-08-08 SI SI201231921T patent/SI3646881T1/sl unknown
- 2012-08-08 JP JP2014524372A patent/JP6161609B2/ja active Active
- 2012-08-08 HU HUE20186935A patent/HUE062640T2/hu unknown
- 2012-08-08 DK DK14184409.2T patent/DK2821080T3/en active
- 2012-08-08 PL PL17154031T patent/PL3195875T3/pl unknown
- 2012-08-08 LT LTEP14184409.2T patent/LT2821080T/lt unknown
- 2012-08-08 DK DK21207717.6T patent/DK4005588T5/da active
- 2012-08-08 RS RS20230518A patent/RS64328B1/sr unknown
- 2012-08-08 ES ES18167552T patent/ES2742163T3/es active Active
- 2012-08-08 EP EP14184409.2A patent/EP2821080B1/en active Active
- 2012-08-08 HR HRP20160145TT patent/HRP20160145T1/hr unknown
- 2012-08-08 ES ES19164277T patent/ES2871405T3/es active Active
- 2012-08-08 HU HUE12753675A patent/HUE027674T2/en unknown
- 2012-08-08 CN CN201710306350.4A patent/CN107281470A/zh active Pending
- 2012-08-08 TR TR2019/00071T patent/TR201900071T4/tr unknown
- 2012-08-08 SI SI201231653T patent/SI3395357T1/sl unknown
- 2012-08-08 LT LTEP17154031.3T patent/LT3195875T/lt unknown
- 2012-08-08 DK DK19164277.6T patent/DK3566712T3/da active
- 2012-08-08 KR KR1020237004855A patent/KR20230024442A/ko not_active Ceased
- 2012-08-08 PL PL19164277T patent/PL3566712T3/pl unknown
- 2012-08-08 EP EP18167552.1A patent/EP3395357B1/en active Active
- 2012-08-08 HR HRP20230607TT patent/HRP20230607T1/hr unknown
- 2012-08-08 EP EP21207717.6A patent/EP4005588B1/en active Active
- 2012-08-08 RU RU2014102924A patent/RU2613324C3/ru active Protection Beyond IP Right Term
- 2012-08-08 ES ES19213649T patent/ES2884947T3/es active Active
- 2012-08-08 EP EP19164277.6A patent/EP3566712B1/en active Active
- 2012-08-08 KR KR1020197024335A patent/KR102111514B1/ko active Active
- 2012-08-08 WO PCT/EP2012/065507 patent/WO2013020996A1/en not_active Ceased
- 2012-08-08 PT PT201869351T patent/PT3756681T/pt unknown
- 2012-08-08 SI SI201230438T patent/SI2741763T1/sl unknown
- 2012-08-08 RS RS20210425A patent/RS61672B1/sr unknown
- 2012-08-08 RS RS20240487A patent/RS65485B1/sr unknown
- 2012-08-08 ES ES20186935T patent/ES2950911T3/es active Active
- 2012-08-08 DK DK12753675.3T patent/DK2741763T3/da active
- 2012-08-08 HU HUE17154031A patent/HUE040058T2/hu unknown
- 2012-08-08 EP EP19213649.7A patent/EP3646881B1/en active Active
- 2012-08-08 RU RU2017106756A patent/RU2739037C3/ru active Protection Beyond IP Right Term
- 2012-08-08 RS RS20190006A patent/RS58198B1/sr unknown
- 2012-08-08 LT LTEP19213649.7T patent/LT3646881T/lt unknown
- 2012-08-08 KR KR1020197036505A patent/KR20190140098A/ko not_active Ceased
- 2012-08-08 RS RS20191038A patent/RS59107B1/sr unknown
- 2012-08-08 CN CN201280038831.7A patent/CN103732243A/zh active Pending
- 2012-08-08 RS RS20160080A patent/RS54561B1/sr unknown
- 2012-08-08 SI SI201231398T patent/SI3195875T1/sl unknown
- 2012-08-08 DK DK17154031.3T patent/DK3195875T3/en active
- 2012-08-08 PT PT192136497T patent/PT3646881T/pt unknown
- 2012-08-08 PT PT212077176T patent/PT4005588T/pt unknown
- 2012-08-08 KR KR1020217023662A patent/KR102353144B1/ko active Active
- 2012-08-08 PL PL21207717.6T patent/PL4005588T3/pl unknown
- 2012-08-08 DK DK20186935.1T patent/DK3756681T5/da active
- 2012-08-08 EP EP17154031.3A patent/EP3195875B1/en active Active
- 2012-08-08 SI SI201232063T patent/SI4005588T1/sl unknown
- 2012-08-08 AU AU2012293647A patent/AU2012293647B2/en active Active
- 2012-08-08 PT PT14184409T patent/PT2821080T/pt unknown
- 2012-08-08 PT PT18167552T patent/PT3395357T/pt unknown
- 2012-08-08 DK DK18167552.1T patent/DK3395357T3/da active
- 2012-08-08 BR BR112014002884A patent/BR112014002884A2/pt not_active Application Discontinuation
- 2012-08-08 ES ES12753675.3T patent/ES2562648T3/es active Active
-
2014
- 2014-01-28 IL IL230696A patent/IL230696B2/en unknown
- 2014-02-06 MX MX2020010991A patent/MX2020010991A/es unknown
- 2014-02-06 MX MX2024008825A patent/MX2024008825A/es unknown
- 2014-02-06 MX MX2024008826A patent/MX2024008826A/es unknown
- 2014-02-07 ZA ZA2014/00952A patent/ZA201400952B/en unknown
-
2015
- 2015-09-01 ZA ZA2015/06382A patent/ZA201506382B/en unknown
-
2016
- 2016-02-10 SM SM201600038T patent/SMT201600038B/it unknown
- 2016-02-18 CY CY20161100142T patent/CY1117214T1/el unknown
- 2016-12-15 AU AU2016273925A patent/AU2016273925B2/en active Active
-
2017
- 2017-03-16 JP JP2017051062A patent/JP6500050B2/ja active Active
- 2017-06-29 US US15/637,962 patent/US10624953B2/en active Active
-
2018
- 2018-05-09 AU AU2018203222A patent/AU2018203222B2/en active Active
- 2018-10-10 HR HRP20181639TT patent/HRP20181639T1/hr unknown
- 2018-12-27 JP JP2018243912A patent/JP6718951B2/ja active Active
-
2019
- 2019-01-03 HR HRP20190023TT patent/HRP20190023T1/hr unknown
- 2019-08-08 HR HRP20191437 patent/HRP20191437T1/hr unknown
-
2020
- 2020-04-17 US US16/851,260 patent/US11291708B2/en active Active
- 2020-06-15 JP JP2020102938A patent/JP7309660B2/ja active Active
-
2021
- 2021-02-18 HR HRP20210277TT patent/HRP20210277T1/hr unknown
- 2021-05-10 HR HRP20210722TT patent/HRP20210722T1/hr unknown
-
2022
- 2022-03-30 US US17/709,305 patent/US12478660B2/en active Active
-
2023
- 2023-07-05 JP JP2023110411A patent/JP2023134561A/ja active Pending
-
2025
- 2025-01-03 US US19/009,834 patent/US20250302923A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2739037C3 (ru) | Композиция для контролируемой стимуляции яичников | |
| PH12018501424B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| GR1007832B (el) | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" | |
| HK1205928A1 (en) | Ocular drug delivery system | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| RU2016122957A (ru) | Способы применения интерлейкина-10 для лечения заболеваний и расстройств | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| JP2017532343A5 (ru) | ||
| RU2017128296A (ru) | Композиция для лечения бесплодия | |
| IN2014DN06920A (ru) | ||
| FI3848028T3 (fi) | Okulaaristen sairauksien hoitomenetelmiä | |
| RU2017126212A (ru) | Композиция | |
| FI3973982T3 (fi) | Koostumus munasarjojen kontrolloituun stimulaatioon | |
| JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
| AR097613A1 (es) | Dosificación de péptidos co-antagonistas gip/glp-1 para administración a humanos | |
| Nakamura | Evidence in the treatment of osteoporosis using weekly teriparatide injections | |
| RU2017140515A (ru) | Способ лечения рассеянного склероза (варианты) | |
| RU2020137769A (ru) | Композиция для контролируемой стимуляции яичников | |
| RU2012109938A (ru) | Способ лечения вирусного гепатита с | |
| TH2001001168A (th) | องค์ประกอบสำหรับการกระตุ้นรังไข่แบบควบคุม | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 | |
| 汪天湛 | Treating type 2 diabetes mellitus patients complicated with metabolic syndrome by benefiting Qi dissolving method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4A | Extension of patent duration |
Effective date: 20210908 |